Key facts
- This page summarizes Ph.D. Robert E. Richard's Form 4 filing for Lyra Therapeutics, Inc. (LYRA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Feb 2023, 16:41.
Ph.D. Robert E. Richard - 31 Jan 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)
- Reporting relationship
- SVP, Technical Operations
- Issuer ticker
- LYRA
- Reported as of
- 31 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2023, 16:41:08 UTC
- Prior SEC filing
- 15 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Cavalier, Attorney-in-Fact for Robert E. Richard, Ph.D.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ph.D. Robert E. Richard filed Form 4 for Lyra Therapeutics, Inc. (LYRA) on 02 Feb 2023.
Change
- Previous filing in this sequence was filed on 15 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LYRA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 31 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LYRA
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +45,000
- Change %
- Price
- $0.000000
- Shares after
- 45,000
- Date
- 31 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,000
- Exercise price
- $2.85
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in four (4) equal annual installments on the first four anniversaries of the grant date such that the RSUs will fully vest on January 31, 2027.
Footnote F2
This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2023.